Investing in the life sciences industry without an understanding of the key regulatory factors that could determine a product’s success or failure could cost you millions of dollars.
As the industry readies itself for the 2019 edition of the annual pilgrimage to the J.P. Morgan Healthcare Conference in San Francisco, our market-leading Global Regulatory Team has prepared a series of updates covering the following topic areas that we hope will help guide your 2019 investment decisions.
Drug pricing and reimbursement
Regulatory changes in Europe
Digital health and medtech
Data privacy and cybersecurity
Cell and gene therapies
European regulatory changes elevate life sciences market uncertainty
In the European Union, the pharmaceutical, biotechnology, and medical device industries are required to constantly adapt to new regulatory developments. Since April 2017, the adoption of medical devices regulations and the EU General Data Protection Regulation (GDPR), the aftermath of Britain’s vote to exit the EU, and the debate over drug pricing have caused challenges for life sciences companies in the EU as they attempt to identify and comply with applicable laws.
Medical devices regulations to establish uniform EU framework
In April 2017, the EU Medical Devices Regulations (MDR) and the In Vitro diagnostic medical Devices Regulation (IVDR) were adopted, which will repeal and replace the EU Medical Devices Directives. Unlike directives, which must be implemented into the national laws of the EU member states, the MDR and IVDR will be directly applicable in the EU member states. The MDR and IVDR are, among other things, intended to establish a uniform, transparent, predictable, and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. They will have significant implications on the way medical devices are currently regulated in the EU. The MDR will be applicable as of May 26, 2020, and the IVDR as of May 26, 2022.
Brexit prompts industry restructuring
With the advent of Brexit, the United Kingdom is set to leave the EU on March 29, 2019, and the European Medicines Agency (EMA) headquarters is moving from London to Amsterdam. For pharmaceutical and biotechnology companies, Brexit has prompted the transfer of several regulatory activities from the UK to other EU member states, including marketing authorizations, batch release, and the Qualified Person for Pharmacovigilance. In addition, many life sciences companies are restructuring their European distribution models; in particular, the Netherlands and Ireland appear to have attracted interest from life sciences companies. While the Brexit vote raised several questions that remain unanswered, EU authorities have recommended that the life sciences industry prepare for a no-deal Brexit.
EU reacts to claims of excessive drug prices
The industry is also faced with the increasing complexities and challenges related to pricing and reimbursement mechanisms, including the increasing use of health technology assessments by the pricing and reimbursement authorities. Although pricing and reimbursement are dealt with at a national EU member state level, there is increased collaboration between the member states. For example, in the "BeNeLuxA" initiative, Belgium, the Netherlands, Luxembourg, Austria, and Ireland have joined forces to exchange information and conduct joint price negotiations for expensive medicines. In 2018, the European Commission issued a much-debated legislative proposal for joint health technology assessment (HTA) among the EU member states.
The debate about drug pricing and perceived excessive pricing has prompted political debate in some EU member states about possibilities to apply cheaper alternatives such as off-label use, pharmacy compounding, personal import from outside the EU, or even compulsory patent licenses. However, some of these suggestions may be questionable from an EU pharmaceutical regulatory law perspective, which requires a marketing authorization based on an appropriate data package in order to place a medicinal product on the market. The antitrust and competition authorities are also investigating potential cases of excessive drug pricing.
Exclusivity rights: court rulings and European Commission assessment
In the area of regulatory data exclusivity and orphan exclusivity in the EU, several court decisions in 2018 – both by the Court of Justice of the European Union and by national courts in the UK and the Netherlands – confirmed the exclusivity rights for innovator pharmaceutical and biotech companies. In 2018-2019, the European Commission is conducting an assessment of the EU regulatory regimes for orphan medicinal products and for pediatric medicinal products. In May 2018, two extensive study reports were published on the economic and legal implications of supplementary protection certificates (SPCs – which extend a patent) and of pharmaceutical incentives such as regulatory data exclusivity and orphan exclusivity. Also in May 2018, the European Commission published a legislative proposal to introduce an SPC manufacturing waiver. The waiver would allow generics and biosimilars manufacturers to manufacture generics/biosimilars in the EU intended for export to outside the EU while an SPC is still in force.
Recent regulatory approvals of medicinal products in the areas of immuno-oncology and gene therapy have attracted attention not only medically and commercially but also contribute to development of regulatory guidance in these areas.
Data privacy affected by GPDR
In May 2018, the GDPR created new challenges for pharmaceutical and biotechnology companies. As a consequence of the GDPR, companies must completely re-assess the way they collect, process, and transfer personal data as part of their activities. As an illustration, the GDPR requires a number of changes to the informed consent forms used by companies to collect the consent of patients for participating to clinical studies.
Increased focus on Sunshine rules and other compliance topics
Last, health care compliance continues to be an important area of focus in the EU. Increasingly, EU member states implement transparency requirements, or so-called “Sunshine rules,” on disclosing transfers of value made to health care professionals, institutions, and patients organizations. The competent authorities appear to take a relatively active approach in investigations and enforcement. Investigations have focused on excessive payments to health care professionals, pre-approval promotion, and direct-to-consumer promotion of prescription-only medicines.